GERMANTOWN, Md., April 11, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, Chief Scientific Officer of Neuralstem,
will be providing a clinical update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy Investor
Day at the Metropolitan Club in New York, NY. The presentation is scheduled for Tuesday, April 17, 2018 at 8:55am ET.
A live audio webcast as well as a video recording of this presentation will be available in the Investors
section of the Company's website at investor.neuralstem.com. The webcast will be archived on the Company's website for 90 days
following the presentation.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet
medical need. The Company has two lead development candidates:
- NSI-189, is a small molecule in clinical development for major depressive disorder and in preclinical development for
Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.
- NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, Amyotrophic Lateral Sclerosis (ALS) and
chronic spinal cord injury (cSCI).
Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell technology.
Cautionary Statement Regarding Forward Looking Information
This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often
be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by
their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our
actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the
development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual
results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential
factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic
reports, including the Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange
Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking
statements.
Contact:
Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
neuralstem@argotpartners.com
